Background {#Sec1}
==========

Exposure to the bacterium *Borrelia burgdorferi* (*sensu lato*), typically transmitted by blacklegged ticks, is the cause of Lyme disease (LD) according to the Centers for Disease Control and Prevention \[[@CR1]\]. Clinically, LD is categorized by early and late disease manifestations \[[@CR2]\]. Following a tick bite, the clinician may consider multiple options, including antimicrobial prophylaxis if the suspected bite occurred within the previous 72 hours, to prevent progression to early LD \[[@CR3]\]. After the diagnosis of early LD has been made, systematic evidence and guideline recommendations support oral beta-lactams (amoxicillin, cefuroxime axetil) and oral tetracyclines (doxycycline) as effective first-line agents based on nine randomized, prospective studies where erythema migrans (an expanding red skin rash) was the disease-defining criterion and the resolution of symptoms the most common outcome \[[@CR2]\]. Other early manifestations of disease may include meningitis, carditis, arthritis, or neurological symptoms \[[@CR4]\].

While antibiotic treatment of early LD may improve the cutaneous symptoms and prevent other early disease complications, only 10--15% of patients develop a late stage disease, commonly referred to as post-treatment Lyme disease syndrome (PTLDS) or late LD \[[@CR5]\]. Despite treatment, some patients will develop PTLDS characterized by nonspecific symptoms such as fatigue, arthralgia and cognitive disturbances. With only a fraction of patients observed in early disease trials progressing on to symptoms synonymous with PTLDS, it is difficult to reach an appropriate sample size to critically evaluate effectiveness between comparators or other sub-group questions linking early disease treatment and PTLDS. PTLDS is frequently characterized by symptoms such as musculoskeletal pain, fatigue and cognitive difficulties which may overlap with other diseases such as fibromyalgia or chronic fatigue syndrome \[[@CR5]\]. Early disease presentation and treatment is relatively straightforward, with little controversy among practitioners. For the proportion of patients who go on to experience the PTLDS complications, the experience can be particularly challenging. A qualitative, phenomenological study of 12 PTLDS patients reported four major themes describing patient experiences and perceptions: (i) changing health status and social impact; (ii) doubts about recovery and the future; (iii) contrasting doctor-patient relationships; and (iv) the use of unconventional therapies \[[@CR6]\].

When health economists develop studies to estimate costs attributable to a given disease, the methodological approach, perspective of the study and source of data may greatly influence the findings and the impact factor of the journal where the results are published \[[@CR7]--[@CR9]\]. These "cost-of-illness" evaluations help translate the burden of disease into dollars, which may be more impactful in the policy arena as decision-makers debate budget priorities \[[@CR10]\]. The variation in methods used in these studies frequently lead to a wide variation of cost estimates for the same disease, limiting the comparability across studies, but provide a necessary first step to account for the economic burden of the disease \[[@CR11]\]. In the case of LD, the financial implications of the disease can vary widely for both the health system and the individual patients experiencing the disease. Previous reviews identified both a range in the methods of estimating costs or cost-effectiveness of treatments or vaccinations for LD \[[@CR12], [@CR13]\]. On the one hand, the prevalence of LD reduces the overall burden of LD at the country-level, but from the patient perspective the costs can be quite substantial \[[@CR13]\]. The aim of this review was to summarize published data on clinical and economic outcomes associated with LD. We also provide recommendations for future cost-effectiveness analyses conducted to evaluate the benefit of LD treatment.

Methods {#Sec2}
=======

Our systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement \[[@CR14]\] (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Due to the heterogeneous nature of publications that include both clinical outcomes and cost estimates, this review only provided an assessment of the studies without a summary estimate from a meta-analysis. A literature search was conducted using EMBASE and PubMed, including studies published through 19 December 2018. The search terms included ((((("lyme\*"\[Title/Abstract\]) OR "borrelia\*"\[Title/Abstract\]) OR "erythema chronicum migrans\*"\[Title/Abstract\]) OR "erythema migrans\*"\[Title/Abstract\])) AND (((((cost\*\[Title/Abstract\]) OR economic\*\[Title/Abstract\]) OR budget\*\[Title/Abstract\]) OR financ\*\[Title/Abstract\]) OR burden\*\[Title/Abstract\]) and results were limited to peer-reviewed publications in English. Titles and abstracts were screened by multiple reviewers for relevance to infectious diseases where LD was reported. Abstracts were reviewed by two authors for screening, with any inclusion discrepancies being discussed for consensus. Original research full-text manuscripts focused on the LD population were included if both clinical and economic outcomes were reported. Studies focused on clinical efficacy or comparative effectiveness without assessing costs or cost-effectiveness were excluded.

Risk of bias was assessed by considering study rigor, type of analysis used, and population as described in the results. Data extraction included the following variables: authors, article title, journal title, year published, type of study, population, outcomes identified in study, any costs identified in study, study funder, and any evidence of direct patient engagement used throughout the study. The type of study was categorized by the research approach which may include clinical trial, observational research using real-world evidence, economic model or simulation-based economic analysis, mixed-methods surveys and qualitative interviews. A narrative synthesis of the findings was structured around the target population characteristics, type of outcome, and type of costs identified. Costs were categorized based on recommendations of the Second Panel on Cost Effectiveness in Health and Medicine ("Second Panel") that include formal health sector, informal health sector, non-health sector, and other \[[@CR15]\]. Formal health sector costs include items such as the costs of medication, inpatient or outpatient care, laboratory tests, or other specialized care directly related to use or consumption of health services. Informal health sector costs include items such as patient or caregiver time or transportation costs that arise when using health services but are often not covered by health insurance. Non-health sector costs capture items such as productivity losses that fall outside the health sector but are often evaluated for the societal perspective in an economic evaluation.

Results {#Sec3}
=======

A total of 832 abstracts were found during the initial search with 327 duplicates, for a total of 505 articles for screening. An additional 476 articles were removed during abstract screening due to lack of relevance or study type. Reviewer agreement for inclusion during screening was 92.7% (468/505). Disagreements were addressed and a total of 39 articles were included in the full-text review. An additional 15 articles were excluded after full-text review for lack of relevance, study type, not a full manuscript, or inappropriate comparators or outcomes assessed. A total of 24 articles were included for qualitative synthesis and full data extraction table is available in Table [1](#Tab1){ref-type="table"} \[[@CR6], [@CR16]--[@CR36]\]. The full results of the search strategy are provided in a PRISMA flow chart (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR14]\].Table 1Summary of characteristics for included studiesReferenceTitleStudy typeCountryFundingPatient engagementAli et al. (2014) \[[@CR6]\]Experiences of patients identifying with chronic Lyme disease in the healthcare system: a qualitative studyQualitative, in-depth interviewsUSAGovernmentYesBerende et al. (2018) \[[@CR16]\]Cost-effectiveness of longer-term *versus* shorter-term provision of antibiotics in patients with persistent symptoms attributed to Lyme diseaseEconomic analysis (alongside clinical trial)NetherlandsGovernmentNoBoudreau et al. (2018) \[[@CR27]\]Motivations and experiences of Canadians seeking treatment for Lyme disease outside of the conventional Canadian health-care systemSurvey; semi-structured; qualitativeCanadaNoneYesDrew & Hewitt (2006) \[[@CR30]\]A qualitative approach to understanding patients' diagnosis of Lyme diseaseQualitative, in-depth interviewsUSAPrivate non-profitYesEckman et al. (1997) \[[@CR31]\]Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritisEconomic analysis (model)USAGovernmentNoFix et al. (1998) \[[@CR32]\]Tick bites and Lyme disease in an endemic settingObservational (prospective cohort)USAGovernmentNoGasmi et al. (2017) \[[@CR33]\]Practices of Lyme disease diagnosis and treatment by general practitioners in Quebec, 2008--2015Observational (retrospective cohort)CanadaGovernmentNoHenningsson et al. (2010) \[[@CR34]\]Neuroborreliosis - an epidemiological, clinical and healthcare cost study from an endemic area in the south-east of SwedenObservational (retrospective cohort)SwedenPrivate non-profitNoHsia et al. (2002) \[[@CR35]\]Cost-effectiveness analysis of the Lyme disease vaccineEconomic analysis (model)USAPrivate non-profitNoJohnson et al. (2011) \[[@CR36]\]Healthcare access and burden of care for patients with Lyme disease: a large United States surveySurvey; quantitativeUSANoneYesJohnson et al. (2014) \[[@CR17]\]Severity of chronic Lyme disease compared to other chronic conditions: a quality of life surveySurvey; quantitativeUSANoneYesJoss et al. (2003) \[[@CR18]\]Lyme disease - what is the cost for Scotland?Observational (prospective cohort)ScotlandGovernmentNoLantos et al. (2013) \[[@CR19]\]Empiric antibiotic treatment of erythema migrans-like skin lesions as a function of geography: a clinical and cost effectiveness modeling studyEconomic analysis (model)USANoneNoLightfoot Jr et al. (1993) \[[@CR20]\]Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease: a cost-effectiveness analysisEconomic analysis (model)USANoneNoLohr et al. (2015) \[[@CR21]\]Epidemiology and cost of hospital care for Lyme borreliosis in Germany: lessons from a health care utilization database analysisObservational (cost-of-illness)GermanyGovernmentNoMaes et al. (1998) \[[@CR29]\]A cost-of-illness study of Lyme disease in the United StatesEconomic analysis (cost-of-illness)USAPrivate for-profitNoMagid et al. (1992) \[[@CR22]\]Prevention of Lyme disease after tick bites - a cost-effectiveness analysisEconomic analysis (model)USAGovernmentNoMeltzer et al. (1999) \[[@CR23]\]The cost effectiveness of vaccinating against Lyme diseaseEconomic analysis (model)USAGovernmentNoNichol et al. (1998) \[[@CR24]\]Test-treatment strategies for patients suspected of having Lyme disease: a cost-effectiveness analysisEconomic analysis (model)USANoneNoShadick et al. (2001) \[[@CR25]\]The cost-effectiveness of vaccination against Lyme diseaseEconomic analysis (model)USAGovernmentNovan den Wijngaard et al. (2017) \[[@CR26]\]The cost of Lyme borreliosisObservational (cost of illness)NetherlandsGovernmentYesZhang et al. (2006) \[[@CR28]\]Economic impact of Lyme diseaseObservational (case-control)USAGovernmentYesFig. 1Review flow diagram according to the preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement \[[@CR14]\]

Of the articles included for analysis, 68% (15/22) were based in the USA, 9% (2/22) in Canada, 9% (2/22) in the Netherlands and only single studies published for populations in Sweden, Scotland and Germany. The majority (55%, 12/22) of the studies were supported by government funding, with "no funding disclosed" (27%, 6/22) and private funding (18%, 4/22) through either a non-profit foundation or for-profit corporation the other two sources of research funding. In terms of patient engagement, only 32% (7/22) incorporated methods that directly engaged with patients either through in-depth interviews or surveys. No studies listed patients or patient caregivers as members of the research team.

Study methods varied from economic models (45%, 10/22), observational studies using real world evidence (29%, 7/24), mixed-method surveys and qualitative interviews (21%, 5/24). Economic models used simulation methods to estimate costs or cost-effectiveness of different treatments or vaccines. Observational studies included cost-of-illness analyses, prospective cohorts and retrospective cohorts. There were no clinical trials that met the review inclusion and exclusion criteria.

Table [2](#Tab2){ref-type="table"} summarizes the most frequent clinical outcomes assessed in LD evaluations with clinical manifestations related to rheumatological, neurological, cardiological and dermatological disorders. Items such as "system challenges" that describe the frustration many LD patients report throughout the course of diagnosis and treatment were identified in a few studies. Psychological impact of disease related to items such as stress, anxiety, or depression were only identified in two studies.Table 2Most frequent outcomes identified in the context of Lyme diseaseOutcomesNo. of studiesBrief descriptionRheumatologic7 \[[@CR21]--[@CR23], [@CR25], [@CR26], [@CR28], [@CR29]\]Including Lyme arthritis, myalgia, or other musculoskeletal manifestationsNeurological7 \[[@CR21]--[@CR23], [@CR25], [@CR26], [@CR28], [@CR29]\]Including encephalopathy, peripheral neuropathy, neuroborrelisosis, bell palsy and meningitisCardiological6 \[[@CR22], [@CR23], [@CR25], [@CR26], [@CR28], [@CR29]\]Including Lyme carditis or other defined cardiac sequelaeDermatological5 \[[@CR22], [@CR25], [@CR26], [@CR28], [@CR29]\]Including erythema migrans, acrodermatitis and chronica atrophicansSystem challenges5 \[[@CR6], [@CR20], [@CR27], [@CR30], [@CR36]\]Frustration with diagnostic delay, access issues, multiple providers, out-of-network providers and other negative system experiencesAdverse events4 \[[@CR19], [@CR20], [@CR25], [@CR35]\]Including major and minor events related to antibiotic treatment or vaccination strategiesQuality of life4 \[[@CR16], [@CR17], [@CR27], [@CR30]\]Including quality-adjusted life-year measures or other specific health related quality of life estimatesOther Lyme sequelae3 \[[@CR25], [@CR26], [@CR29]\]Including lymphocytoma, ocular manifestations, headache, acute back pain and neck painPsychological2 \[[@CR6], [@CR30]\]Including stress, anxiety, or depression

Table [3](#Tab3){ref-type="table"} summarizes the most frequent costs with formal health sector costs reported in the majority of studies. Productivity losses due to illness were the most common costs identified outside of the health sector. Health system issues, travel and informal care costs were less frequently identified.Table 3Most frequent costs identified in the context of Lyme diseaseCostsNo. of studiesBrief descriptionCost categoryIntervention18 \[[@CR17], [@CR18], [@CR20]--[@CR26], [@CR28], [@CR29], [@CR31]--[@CR35]\]Antibiotic treatments or vaccine interventions studiedFormal health sectorHealth resource utilization17 \[[@CR17], [@CR18], [@CR20]--[@CR26], [@CR28], [@CR29], [@CR31], [@CR32], [@CR34], [@CR35]\]Office visits, hospitalizations, management of adverse events and other direct medical costs pursuant to common Lyme sequelaeFormal health sectorProductivity losses10 \[[@CR16]--[@CR18], [@CR21], [@CR23], [@CR26], [@CR28]--[@CR30], [@CR36]\]Any absenteeism or presenteeism costs due to diseaseNon-health sectorSerological testing9 \[[@CR18], [@CR22]--[@CR26], [@CR28], [@CR32], [@CR33]\]Diagnostic testingFormal health sectorHealth system issues5 \[[@CR6], [@CR20], [@CR28], [@CR30], [@CR36]\]Costs experienced with health system navigation including diagnostic delays, unconventional therapies, costs of inconvenience and costs related to concern for false positive testsOtherTravel expenses4 \[[@CR16], [@CR27], [@CR28], [@CR36]\]Any travel expenses related to Lyme sequelaeInformal health sectorInformal care costs2 \[[@CR26], [@CR28]\]Caregiver time costsInformal health sector

Discussion {#Sec4}
==========

Most studies evaluating both the clinical and economic impact of LD focused on direct medical costs frequently identified as part of the formal health sector perspective in economic evaluations \[[@CR15]\]. Non-health sector costs were identified in several studies, but these were limited to productivity losses (absenteeism and presenteeism). Other non-health sector cost categories such as consumption, social services, education, housing, or environment were not identified \[[@CR15]\]. In 2018, the International Society of Pharmacoeconomics and Outcomes Research formed a special task force on value in health care that recognized several elements of value not frequently identified in conventional economic evaluations including "reduction in uncertainty, fear of contagion, insurance value, severity of disease, value of hope, real option value, equity, and scientific spillovers" \[[@CR37]\]. When considering potential elements of value that may be of interest to LD patients, many of these areas have yet to be explored in a more formal, systematic way. When LD patients were engaged directly through either structured interviews or surveys, uncertainty regarding diagnosis and treatment are common themes and sources of frustration for patients \[[@CR6], [@CR27], [@CR30], [@CR36]\].

Studies that capture both direct and indirect costs of LD demonstrate how perspective impacts costs estimates. For example, Lohr et al. \[[@CR21]\] estimated that median costs for LD hospitalizations in Germany from 2008 to 2011 were €3917 for adolescents and €2843 for adults, or about 23.7 million Euros annually. They further estimated indirect costs based on productivity and work absences to account for an additional 7.1 million Euros \[[@CR21]\]. van den Wijngaard et al. \[[@CR26]\] included both direct and indirect costs in their cost-of-illness analysis of LD in the Netherlands to estimate the mean costs were approximately €5700 per patient annually in 2014. Maes et al. \[[@CR29]\] estimated direct and indirect costs of LD in the USA to vary greatly between early and late disseminated disease. They reported direct costs in 1996 ranging from 731--3445 USD per year and 2740--8270 USD per year for early and late disseminated disease, respectively \[[@CR29]\]. When extending to indirect costs from time or productivity loss, costs ranged from as low as 89--3152 USD, influenced significantly by the severity of disease \[[@CR29]\].

Economic evaluation focusing on the direct costs associated with an intervention and cost savings related to formal care are useful for health insurers (public or private) typically responsible for purchasing these services as part of the medical or pharmacy benefits in the patient's health plan. Direct health care costs are frequently assessed to inform this payer perspective. For example, an observational study by Adrion et al. \[[@CR38]\] focusing on PTLDS estimated that 52,795 commercially insured patients experienced an average of 2968 USD higher direct health care costs annually compared to matched controls. Unfortunately, this limited focus may miss significant costs experienced by the patient that also influence decision-making at the patient- and provider-level. Additionally, if the evaluation solely focuses on the impact on the individual patient, any potential spillover effects on the immediate family or caregivers involved \[[@CR39], [@CR40]\].

In the case of LD, many patients report other factors that are not typically incorporated into cost-effectiveness analyses. When an LD patient experiences frustration with the health system due to system challenges such as a provider being dismissive of the diagnosis, it is difficult to capture the economic consequences that may result from the negative patient-provider interaction \[[@CR6]\]. These patient experience variables are unavailable in cost-of-illness studies using administrative claims data to capture costs while the cost data are often missing from prospective clinical studies where the patient experience may be better documented.

In some cases, researchers focus on broader country-level economic burden or impact of LD on a total population. This may be very useful for determining whether investing in universal vaccinations for a large population would be cost effective or if a more targeted strategy would be preferred \[[@CR12]\]. Similar to studies focused on the costs attributed to LD, the approach to costing (direct health costs or including non-health costs) plays a role in the evaluation. However, these studies are quite sensitive to incidence rates, so ensuring accurate diagnoses of new cases is critical to the accuracy of these models \[[@CR12], [@CR35]\]. Additionally, public perceptions and trust in vaccine recommendations may also influence one's willingness-to-pay for a vaccine \[[@CR41]\]. Considering communication strategies or efforts to improve these other factors may be important for economic models that focus on vaccines and prevention.

This review was limited by study type and methodological variation within studies identified for inclusion, limiting the ability for the quantitative synthesis of costs for each category. Including studies from all over the world also limits the generalizability to patients within any single country's health system. For example, costs of copayments and other out-of-pocket expenditures may not be as significant for patients residing in a country with a single-payer system with less coinsurance expectations on the population. Our targeted search strategy focused on abstract and titles for keywords may have limited the number of potential abstracts for review. Additionally, we screened to focus on studies that included both clinical and economic outcomes, potentially limiting our inclusion of studies that purely focused on either independently. For example, researchers have estimated other indirect costs attributable to LD such as "spending less time outdoors" and "less outdoor recreation" potentially leading to a substantial welfare loss each year \[[@CR42]\].

Recommendations for future economic evaluations of LD {#Sec5}
=====================================================

To align with best practices frequently cited by health economists, we recommend LD researchers consider the following \[[@CR43]\]:*Report both health sector and societal perspectives* -- patients with LD experience significant costs outside of the formal health system (e.g. absenteeism, presenteeism, time, care not covered by health insurance) that should be captured in a societal perspective model.*Perform multiple sensitivity analyses on key assumptions* -- as with any economic model, uncertainty analyses help test the main assumptions. Misdiagnoses, costs outside traditional health systems, patient heterogeneity, and provider heterogeneity may significantly impact the results of any cost-effectiveness or budget impact model in LD but may be difficult to ascertain. Expert opinion may be the best source for some of these variables and it will be important to test many of these assumptions independently.*Engage LD patients throughout the study* -- by working directly with LD patients as advisors during economic model development, health economists can gain valuable perspectives that may not be captured in the published literature.

Conclusions {#Sec6}
===========

Evaluations of clinical and economic outcomes of LD are primarily economic models or observational analyses and focus on formal health care. Less evidence exists for the broader impact of informal care or costs outside of the health system frequently experienced by LD patients.

Supplementary information
=========================

 {#Sec7}

###### 

**Additional file 1: Table S1.** PRISMA checklist.

LD

:   Lyme disease

PTLDS

:   post-treatment Lyme disease syndrome

PRISMA

:   preferred reporting items for systematic reviews and meta-analyses

**Publisher\'s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
=========================

**Supplementary information** accompanies this paper at 10.1186/s13071-020-04214-y.

Not applicable.

All authors had full access to all the data in the review and take responsibility for the integrity of analysis. TJM and KS-W conceived and designed the study. TJM and KS-W acquired, analyzed and interpreted data. TJM drafted the manuscript and supervised the study. KS-W provided critical revisions. All authors read and approved the final manuscript.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

All data generated during this study are included in this published article.

Not applicable.

Not applicable.

TJM reports personal fees from Bristol-Myers Squibb, the National Health Council and the Massachusetts Health Policy Commission for work unrelated to this research. KS-W declares that she has no competing interests.
